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Abstract		
Introduction	Accurate	assessment	of	muscle	insulin	sensitivity	requires	measurement	of	insulin	concentration	in	interstitial	fluid	(ISF),	but	has	proved	difficult.		We	aimed	to	optimise	measurement	of	ISF	insulin	concentrations	in	rat	muscles	in	vivo	using	microdialysis.		
Methods	Factorial	experimental	design	experiments	were	performed	in	vitro	to	determine	optimal	conditions	for	insulin	recovery	with	microdialysis	probes.		These	conditions	were	tested	in	vivo,	adjusted	appropriately	and	used	in	lean	and	obese	Zucker	rats	to	compare	ISF	insulin	concentrations	basally	and	during	hyperinsulinaemic-euglycaemic	(HE)	clamp.		
Results	Optimal	conditions	in	vivo	were:	a	100	kDa	microdialysis	probe	inserted	in	muscle,	perfused	with	1%	BSA,	1.5mM	glucose	in	0.9%	sodium	chloride	at	1μl/min.	Samples	were	collected	into	siliconised	glass	microvials.	As	a	reference	for	insulin,	we	established	a	protocol	of	inulin	infusion,	beginning	at	-80min	and	reaching	equilibrium	within	60min.		HE	clamp,	beginning	at	0min,	increased	ISF	insulin	concentration	from	122	±	56		basally	to	429	±	180pmol/L	(P	<	0.05)	in	lean	rats	and	from	643	±	165	to	1087	±	243pmol/L	(P	=	0.07)	in	obese	rats;	ISF	insulin	concentrations	were	significantly	higher	throughout	in	obese	rats.		The	difference	between	ISF	and	plasma	insulin	concentration	(ISF:plasma	ratio)	was	substantially	higher	in	obese	rats,	but	fell	to	similar	values	in	obese	and	lean	rats	during	HE	clamp.	
Discussion	Optimising	insulin	recovery	with	microdialysis	allowed	accurate	measurement	of	basal	ISF	insulin	in	muscle	of	lean	and	obese	Zucker	rats	and	indicates	insulin	transport	across	capillaries	is	impaired	in	obese	rats,	basally	and	during	hyperinsulinaemia.		
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Abbreviations:	ISF;	interstitial	fluid,	HE;	hyperinsulinaemic-euglycaemic	clamp,	TET;	transendothelial	transport,	IRK;	insulin	receptor	kinase,	RR;	relative	recovery,	BSA;	bovine	serum	albumin,	I:P	ratio;		interstitial	to	plasma	ratio,	MI;	insulin	sensitivity.		 	
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1	Introduction		The	prevalence	of	obesity	and	diabetes	is	increasing	worldwide.		Thus,	there	is	an	associated	need	for	accurate	assessment	of	the	factors	that	contribute	to	insulin	sensitivity	and	resistance	in	animal	models	of	these	conditions.			Generally,	insulin	sensitivity	of	skeletal	muscle,	one	of	the	major	tissues	for	glucose	disposal,	is	assessed	from	the	relationship	between	plasma	level	of	insulin	and	glucose	uptake.		However,	plasma	insulin	concentration	is	not	a	good	index	of	the	concentration	of	insulin	in	the	interstitial	fluid	(ISF)	of	skeletal	muscle	from	where	it	accesses	insulin	receptors	on	the	sarcolemma.		Indeed,	it	is	well	established	that	the	plasma	insulin	concentration	required	to	increase	glucose	disposal	rate	in	vivo	is	significantly	higher	than	that	required	in	vitro	(Poulin,	Steil,	Moore,	Ader,	&	Bergman,	1994).		Moreover,	the	rate	of	increase	in	glucose	uptake	during	hyperinsulinaemic-euglycaemic	(HE)	clamp	is	delayed	compared	to	the	change	in	plasma	insulin	concentration	(Castillo,	Bogardus,	Bergman,	Thuillez,	&	Lillioja,	1994).			The	disparities	between	plasma	and	ISF	insulin	concentrations	are	partly	explained	by	the	fact	that	insulin	must	cross	the	capillaries	in	order	to	reach	the	ISF.		Trans-endothelial	transport	(TET)	of	insulin	is	regulated	by	an	insulin-receptor	mediated	process	on	the	endothelial	cells.		Insulin	also	acts	on	insulin	receptors	on	resistance	vessels	and	terminal	arterioles	to	increase	muscle	blood	flow	and	the	capillary	surface	area	for	exchange	(Barrett	et	al,	2009;	2011).		Thus,	the	relationship	between	plasma	ISF	and	ISF	insulin	is	dependent	on	the	sensitivity	of	the	insulin	receptors	at	these	different	vascular	sites	and	these	factors	in	turn,	affect	estimates	of	muscle	insulin	sensitivity.		Nevertheless,	a	full	appreciation	of	the	sensitivity	of	skeletal	muscle	to	insulin	ultimately	requires	that	insulin	concentrations	be	measured	in	ISF.	
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	Insulin	concentration	in	lymph	has	been	used	as	a	surrogate	for	ISF	insulin	concentration	in	hindlimb	of	humans	(Castillo	et	al.,	1994)	and	rats	(Poulin	et	al.,	1994).		Such	measurements	indicated	lymph	concentrations	are	substantially	lower	than	those	in	plasma	and	correlate	better	with	glucose	uptake	than	plasma	insulin	concentration	(Yang,	Hope,	Ader,	&	Bergman,	1989).		However,	lymph	insulin	concentration	is	not	an	accurate	assessment	of	ISF	insulin	because	lymph	drainage	from	hindlimb	derives	from	skin,	adipose	tissue	and	bone,	as	well	as	muscle.		The	alternative	is	to	use	microdialysis	to	directly	assay	insulin	in	muscle	ISF	as	has	been	reported	in	humans	and	rats	(e.g.	Sjostrand	et	al.,	2000;	Gudbjornsdottir,	Sjostrand,	Strindberg,	&	Lonnroth,	2005;	Holmang,	Mimura,	Bjorntorp,	&	Lonnroth,	1997).		However,	this	is	technically	challenging	particularly	in	rodents,	because	insulin	is	a	large	molecule	that	diffuses	slowly	across	the	pores	of	dialysis	membranes,	and	because	insulin	concentration	is	notoriously	difficult	to	measure	in	low	concentrations	in	small	fluid	volumes.		Indeed,	the	low	concentrations	of	insulin	in	ISF	under	basal	conditions	have	not	yet	been	measured	accurately	in	the	rat.			Thus,	the	primary	aims	of	the	present	study	were	to	optimise	the	microdialysis	methodology	in	vitro	whilst	employing	validated	techniques	for	assaying	low	concentrations	of	insulin	in	small	fluid	volumes.		We	then	adapted	these	techniques	so	that	they	could	be	used	accurately	and	reliably	to	measure	ISF	insulin	concentrations	in	
vivo	in	the	rat.		We	also	established	than	an	inulin	infusion	given	from	80min	before	the	start	of	the	experiment	proper,	could	serve	as	an	effective	reference	for	insulin.		Our	final	aim	was	to	measure	ISF	insulin	concentration	in	hindlimb	muscle	of	lean	and	obese	Zucker	rats	in	the	basal	state	and	during	HE	clamp	so	as	to	clarify	the	relationship	
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between	plasma	and	ISF	insulin	and	to	allow	direct	estimates	of	skeletal	muscle	insulin	sensitivity.	
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2		Methods	
	
2.1	Validation	of	the	microdialysis	method	in	vitro	Factorial	experimental	design	experiments	were	performed	to	determine	the	best	conditions	for	recovery	of	insulin.		All	equipment	was	purchased	from	CMA	Microdialysis,	Sweden	via	Linton	Instrumentation,	Norfolk,	UK	unless	stated	otherwise.			
2.1.1	Reagent	preparation.		All	reagents	were	prepared	on	the	day	of	study	unless	stated	otherwise.		
Microdialysis	perfusion	fluid	was	prepared	using	10%	BSA	and	20%	(w/v)	glucose.		A	working	solution	of	1%	BSA	and	1.5mmol/L	glucose	was	prepared	in	0.9%	sodium	chloride	and	delivered	at	1µl/min.	
Inulin	A	stock	solution	of	10mg/ml	inulin	was	diluted	in	0.9%	sodium	chloride	to	a	solution	concentration	of	25µg/ml.	
Human	insulin	was	prepared	by	diluting	human	insulin	(Actrapid®,	Novo	Nordisk,	Denmark)	in	2%	BSA	(in	0.9%	sodium	chloride)	to	concentrations	of	7000,	3000,	1000	and	300pmol/L.			
2.1.2	Microdialysis	probe	preparation	Microdialysis	probes	(CMA	20),	10mm	in	length	with	cut-off	pore	sizes	of	55	or	100kDa,	were	connected	via	fluorinated	ethylene	propylene	(FEP)	tubing	and	tubing	adapters.		The	inlet	FEP	tubing	was	connected	to	a	1ml	microsyringe	in	an	infusion	pump	(CMA	402	dual	syringe	pump)	filled	with	perfusion	fluid	(see	above).		Insulin	was	diluted	to	7000pmol/L	as	detailed	above	and	1ml	of	solution	was	placed	in	siliconised	glass	vials.	Glass	vials	were	secured	in	a	CMA	130	in	vitro	stand	and	microdialysis	probes	were	
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submerged	in	test	solution	and	secured	with	the	clips	provided.		Probes	were	equilibrated	for	40min	with	each	new	set	of	conditions.		The	rate	of	perfusion	was	1,	2	or	2.5µl/min.		All	equipment	and	tubing	was	either	treated	with	Sigmacote®	(Sigma-Aldrich	Ltd,	UK),	or	it	was	not.		Following	initial	experiments	to	test	the	optimum	conditions	for	insulin	recovery,	further	experiments	were	conducted	to	assess	recovery	at	different	concentrations	of	insulin	(3000,	1000	and	300pmol/L)	and	inulin	(25µg/ml).		
2.1.3	Sample	collection	and	analyses	The	perfusate	was	collected	in	either	plastic,	or	glass	vials:	40min	samples	were	collected,	split	equally	for	storage	and	analysed	in	duplicate.		Insulin	and	inulin	were	assayed	with	ELISA	Kits	(see	2.2.7).	
	
2.2	Refinement	of	microdialysis	methodology	in	vivo		All	experiments	were	conducted	in	accordance	to	the	Animal	Scientific	Procedures	Act	1986	and	associated	guidelines,	EU	Directive	2010/63/EU	for	animal	experiments.		They	were	performed	on	either	male	Wistar	rats,	or	male	lean	or	obese	Zucker	rats	(supplied	by	Charles	River,	Kent,	UK).		Anaesthesia	was	induced	with	an	intra-peritoneal	(i.p.)	injection	of	160-190mg/kg	sodium-thiobutabarbitol	(Inactin®,	Sigma-Aldrich	Ltd,	UK)	and	supplemented	as	required,	with	bolus	doses	of	0.5ml,	or	by	increasing	the	infusion	rate	of	anaesthetic	via	a	cannula	placed	in	the	jugular	vein.		At	the	end	of	the	experimental	protocol,	the	animal	was	humanely	killed	by	overdose	of	sodium-thiobutabarbitol.		Death	was	confirmed	by	cervical	dislocation.		
2.2.1	Experimental	groups	
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2.2.1.1		Inulin	infusion			Experiments	were	performed	on	3	anaesthetised	male	Wistar	rats	(weight	222	±	15g)	to	establish	whether	inulin	could	be	given	by	infusion	so	as	to	provide	a	reference	for	insulin.		The	inulin	infusion	protocol	was	based	on	modelling	of	kinetics	in	preliminary	experiments	not	reported	here.		Thus,	insulin	was	given	as	a	50mg/kg	bolus	followed	by	infusion	at	2mg/kg/min	for	180min.		Blood	samples	for	analysis	were	taken	at	1	and	5min	and	then	at	15min	intervals.		Each	sample	was	centrifuged	at	13,	000RPM	for	5min	at	4oC	and	plasma	was	stored	at	5oC	and	analysed	<1week	after	collection.		In	the	preliminary	inulin	kinetic	experiments,	we	tested	whether	samples	could	be	frozen	prior	to	analysis	of	inulin;	these	findings	are	shown	in	Supplementary	Data	Figure	1.		
2.2.1.2	Combined	inulin	infusion	and	HE	clamp		Experiments	were	performed	on	4	male	Wistar	rats	(weight	222	±	15g);	see	Supplementary	Data	for	details.		The	methodology	tested	in	these	experiments	was	adopted	for	the	experiments	proper	and	is	described	in	detail	below	(see	2.2.2	-	2.2.9).		These	experiments	were	also	used	to	compare	recovery	of	insulin	with	microdialysis	probes	at	different	pore	cut-off	sizes	of	55	and	100kDa.		Therefore,	half	of	the	probes	prepared	and	inserted	as	described	in	2.2.4	and	2.2.5	were	55kDa	and	half	were	100kDa.			
2.2.1.3	Use	of	validated	microdialysis	methodology	during	HE	clamp		Experiments	were	performed	on	6	lean	and	5	obese	Zucker	rats.	Full	methodology	is	described	below	(see2.2.2	–	2.2.9).		
2.2.2	Animal	husbandry		
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Animals	were	housed	in	cages	on	a	controlled	12	hour	Light/Dark	cycle,	(6am:	6pm)	and	fed	standard	chow	(SDS	Rat	and	Mouse	No.	1,	2.61	kcal/g	of	ration	or	9.24%	kcal	of	fat)	and	water	ad	libitum.		The	day	before	the	experiment	proper,	each	rat	received	a	fixed	ration:	16	or	10g	rat	chow	(obese	and	lean	respectively)	at	16:00	to	provide	sufficient	food	until	approximately	midnight.		Thus,	the	rat	was	non-absorptive,	but	not	starved	during	the	HE	clamp	protocol.			
2.2.3	Preparation	of	reagents		
All	reagents	were	prepared	on	the	day	of	study,	unless	otherwise	indicated.	Approximately,	80%	of	glucose	uptake	occurs	in	the	skeletal	muscle	(Defronzo,	Ferrannini,	Sato,	&	Felig,	1981).		Thus,	insulin	sensitivity	is	expressed	per	fat-free	mass	(lean	body	mass;	LBM)	rather	than	body	weight	(Muniyappa,	Lee,	Chen,	&	Quon,	2008)	and	the	HE	clamp	and	inulin	concentration	were	delivered	according	to	LBM.		LBM	was	estimated	from	empirical	linear	regression	formulae	derived	from	body	composition	analysis	of	Zucker	rats	performed	in-house.		The	equations	used	for	the	Lean	and	Obese	Zucker	rat	were	LBM	(g)	=	31	+	0.77	x	BW	(g)	and	59	+	0.50	x	BW	(g)	respectively.	
	
Microdialysis	perfusion	fluid	was	prepared	using	10	%	BSA	and	20	%	(w/v)	glucose.	A	working	solution	of	1	%	BSA	and	1.5mmol/L	glucose	was	prepared	in	0.9%	sodium	chloride	and	delivered	at	1µl/min.	
Inulin	A	stock	solution	of	10mg/ml	inulin	was	diluted	in	0.9%	sodium	chloride	so	that	we	could	deliver	both	a	1mg/kgLBM	bolus	and	0.08mg/kgLBM/min	infusion.		The	1mg/kgLBM	bolus	dose	was	given	as	0.125ml	bolus	over	30	seconds.		The	0.08	mg/kgLBM/min	infusion	was	then	given	as	10µl/min	for	the	rest	of	the	experiment.	
Human	insulin	was	prepared	by	diluting	human	insulin	(Actrapid®,	Novo	Nordisk,	
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Denmark)	in	10ml	of	Haemaccel®.		The	volume	of	stock	human	insulin	solution	added	to	the	Haemaccel®	was	determined	according	to	the	experimental	group	and	lean	body	mass	in	kg,	kgLBM.		The	volume	infusion	rate	was	fixed	in	all	experiments	to	10µl/min.		
2.2.4	Microdialysis	probe	preparation	Each	probe	(100kDa	cut-off)	was	perfused	in	vitro	prior	to	and	during	surgical	preparation	of	the	rat	(>30min).		The	probe	inlet	and	outlet	tubing	was	cut	to	5cm	and	connected	to	siliconised	‘FEP’	tubing	by	using	adapters.		The	inlet	tubing	was	connected	to	a	1ml	microsyringe	containing	perfusion	fluid.		The	outlet	tubing	was	cut	to	45cm.	The	probes	were	placed	in	an	in	vitro	stand	and	the	syringe	pump	was	started	at	1µl/min	and	allowed	to	run	until	probe	insertion;	perfusion	fluid	collected	during	this	period	was	discarded.			
2.2.5	Surgical	procedure	and	baseline	measurements	On	the	morning	of	the	experiment	proper,	the	rat	was	anaesthetised	with	an	i.p.	injection	of	160-190mg/kg	sodium-thiobutabarbitol	as	described	in	2.2	above.		The	right	jugular	vein	was	cannulated	with	five	cannulae	for	infusions	of	insulin,	glucose,	inulin,	and	sodium-thiobutabarbitol.		The	trachea	was	cannulated	and	medical	O2	was	directed	over	the	opening	at	free	flow	to	ensure	adequate	arterial	oxygenation.		The	left	carotid	artery	was	cannulated	for	blood	sampling	and	recording	of	arterial	blood	pressure	(ABP);	mean	ABP	(MABP)	was	derived	on-line.		All	cannulae	were	filled	with	20mM	sodium	citrate	solution	to	prevent	clotting.		Carotid	artery	catheter	patency	was	maintained	by	continuous	infusion	(10μl/min)	of	20mM	sodium	citrate	solution.		Body	temperature	was	monitored	and	maintained	at	37°C	using	a	rectal	probe	and	heat	blanket	(Harvard	Apparatus	Ltd,	UK).		
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	Following	surgery,	the	rat	was	allowed	to	stabilize	for	40min	from	-120	to	-80min	(see	Figure	1).		During	this	time,	a	microdialysis	probe	was	inserted	into	the	tibialis	anterior	muscle	of	each	hindlimb	at	45o	to	the	skin	surface	by	using	a	guide	needle	and	split	tubing.		It	was	tunnelled	~5mm	under	the	surface	of	the	skin	parallel	to	the	surface.		All	tubing	and	equipment	was	siliconised	on	the	basis	of	the	in	vitro	studies	(see	Results).		The	outlet	FEP	tubing	was	fed	into	the	refrigerated	microfraction	collector	(CMA	470)	set	at	6oC	and	was	positioned	below	the	level	of	the	rat.		The	length	of	outlet	tubing	was	calculated	from	the	internal	diameter	to	correspond	to	a	5	min	time	delay	in	the	transport	of	each	fraction	collected	from	the	rat	to	the	siliconised	glass	microvial	when	perfusion	was	set	at	1µl/min,	as	determined	by	the	in	vitro	measurements	(see	Results	3.1).	Each	individual	microdialysis	probe	used	in	vivo	was	calibrated	for	recovery	of	insulin	as	described	in	2.2.8.			A	baseline	arterial	blood	sample	(200µl)	was	taken	at	-90min	from	the	carotid	artery	into	potassium-EDTA	coated	tubes	(Microvette®,	Sarstedt	Ltd.,	UK)	and	immediately	centrifuged.		Plasma	samples	were	split	and	stored	at	-20°C	for	later	determination	of	insulin	concentration,	or	at	4°C	for	determination	of	inulin	concentration.		Additionally,	a	small	drop	of	arterial	blood	was	assayed	for	blood	glucose	by	using	a	test	strip	(Roche	Accu-chek®).			At	-80min,	infusion	of	inert	inulin	was	commenced	as	a	bolus	(0.125ml)	followed	immediately	by	infusion	at	10µl/min.		Collection	by	the	microfraction	collector	was	therefore	started	at	-75min	and	a	fraction	was	collected	every	40min.		These	fractions	were	directly	correlated	with	plasma	samples	taken	over	the	same	periods,	an	additional	arterial	blood	sample	being	taken	at	-60min	to	correspond	with	ISF	Sample	1	(Figure	1).		Microdialysis	probes	were	checked	regularly	for	patency	and	flushed	at	
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20μl/min	for	~	30s	if	necessary.		Microdialysis	probe	placement	was	checked	by	dissection	post	mortem.	
	
2.2.6	Hyperinsulinaemic-euglycaemic	clamp	As	shown	in	Figure	1,	blood	glucose	concentration	for	the	basal	phase	of	the	HE	clamp	was	taken	as	the	average	of	measurements	taken	at	-20,	-10	and	0min	by	using	the	test	strips.		Arterial	blood	samples	(200µl)	for	off-line	analysis	were	collected	via	the	carotid	cannula	at	-20	and	0min.		Sample	2	of	ISF	corresponded	to	the	basal	phase	of	the	HE	clamp.		The	HE	clamp	phase	began	after	collection	of	the	0min	sample.		Human	insulin	was	infused	via	the	jugular	vein	using	a	digital	syringe	pump	at	10μl/min.		The	insulin	concentration	was	calculated	according	to	lean	body	mass	(LBM,	see	above)	and	delivered	at	10	and	20mU/kgLBM/min	of	insulin	for	lean	and	obese	rats	respectively.		Thereafter,	arterial	blood	glucose	concentrations	were	determined	every	3	to	5min	and	blood	glucose	was	clamped	at	the	basal	(euglycaemic)	concentration	by	infusing	glucose	20%	(w/v)	at	a	variable	rate	by	using	the	digital	syringe	pump.		The	infusion	rate	required	to	achieve	this	was	noted	so	that	glucose	infusion	rate	(GIR)	could	be	calculated	and	used	to	calculate	insulin	sensitivity	(MI;	see	2.2.8).		Additional	arterial	blood	samples	for	analysis	of	glucose,	insulin	and	inulin	were	taken	at	20,	40,	60,	70	and	80min.			
2.2.7	Sample	analysis			Plasma	glucose	was	determined	by	using	a	Clinical	Analyser,	(YSI	(UK)	Ltd.,	Hampshire,	UK).			Inulin	concentration	in	the	in	vitro	and	in	vivo	studies	was	assayed	by	using	the	BioPal	FIT-GFR	kit	(BioPal,	Worcester,	Massachusetts).			
	 14	
In	initial	in	vitro	studies	insulin	was	assayed	with	the	Mercodia	Ultrasensitive	Rat	Insulin	Kit,	which	has	a	stated	sensitivity	range	of	0.9-120pmol/L	and	should	therefore	detect	concentrations	lower	than	those	detected	by	the	Crystal	Chem	Rat	Insulin	ELISA	kit	(nominally	17.4	-	11,136pmol/L).		However,	we	established	that	the	Mercodia	kit	could	not	be	used	with	a	volume	less	than	the	recommended	25µl,	which	would	have	allowed	only	2-3	samples	to	be	assayed	over	the	period	of	the	HE	clamp.		The	Crystal	Chem	kit	has	the	major	advantage	of	only	requiring	a	sample	volume	of	5µl.		Additionally,	the	Crystal	Chem	assay	has	been	validated	by	the	Analytical	Group,	CVGI,	AstraZeneca,	Alderley	Park	for	the	measurement	of	insulin	in	the	range	5.4	-	11,136pmol/L.		Insulin	concentration	in	samples	taken	from	the	in	vitro	and	in	vivo	studies	were	therefore	analysed	by	using	the	same	ultrasensitive	rat	insulin	kit	(Ultrasensitive	Rat	Insulin	ELISA	Kit,	Crystal	Chem,	Illinois,	USA).		As	the	ELISA	kit	used	for	insulin	assay	cross-reacts	with	the	human	insulin	used	for	the	HE	clamp,	two	standard	calibration	curves	were	run	on	the	ELISA	plate,	one	using	the	rat	insulin	supplied	in	the	kit	and	the	other	with	human	insulin	spiked	into	rat	plasma	ISF.		Samples	(plasma	and	ISF)	before	the	initiation	of	insulin	infusion	were	read	off	the	rat	standard	curve	and	samples	(plasma	and	ISF)	collected	after	the	initiation	of	insulin	infusion	were	read	off	the	human	standard	curve.	(See	Discussion	for	consideration	of	outcomes).		For	ISF	sample	collection,	the	outlet	tubing	volume	was	calculated	using	the	internal	diameter	of	the	FEP	tubing.		An	outlet	tubing	length	of	45cm	was	calculated	to	have	a	volume	of	5µl	and	therefore	to	correspond	to	a	5min	time	delay	from	tissue	to	collection	vial.		The	CMA	470	Refrigerated	microfraction	collector	was	therefore	started	5min	after	the	inulin	infusion	and	could	then	be	taken	to	represent	real	time	measurements	of	tissue	concentrations,	as	the	delay	in	the	sample	reaching	the	collection	vial	was	
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accounted	for.		The	ISF	Samples	(microdialysate	fractions	of	40µl	collected	over	40min	in	the	microvials	were	split	equally	and	stored	at	-80°C	for	later	determination	of	insulin,	or	at	5°C	for	determination	of	inulin.		A	15µl	sample	of	ISF	was	required	in	order	that	it	could	be	diluted	1	in	10	to	provide	a	large	enough	volume	to	test	50µl	of	diluted	sample	in	duplicate	with	the	BioPAL	FIT-GFR	(Inulin)	kit.		A	15µl	ISF	sample	was	also	required	to	test	ISF	samples	neat	on	the	Crystal	Chem	Rat	Ultra	Sensitive	Insulin	kit.		Therefore,	microdialysate	fractions	(40µl)	collected	over	40min	allowed	for	dead	space	and	any	small	ultrafiltration	of	samples,	whilst	ensuring	there	was	enough	fluid	volume	for	analysis	of	each	fraction.		
2.2.8	Calculations	
2.2.8.1	Insulin	Sensitivity	(MI)		MI	was	calculated	as:		 MI	(µmol/kg/min	per	pmol/L)	=	GIR	(µmol/kg/min)/Plasma	insulin	(pmol/L)		Where	GIR	is	the	steady	state	glucose	infusion	rate	at	the	end	of	HE	clamp	and	plasma	insulin	concentration	represents	measurements	taken	at	corresponding	time	points.		GIR	was	expressed	as	mg/kgLBM/min.			
2.2.8.2	Insulin	recovery	in	vivo		ISF	concentrations	of	insulin	and	inulin	obtained	from	each	rat	were	averaged	to	obtain	a	mean	measure	for	each	rat.		Actual	ISF	insulin	concentration	was	calculated	from	the	measured	ISF	insulin	concentration	in	vivo,	and	adjusted	per	recovery	of	inulin	in	vivo	by	
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using	the	external	reference	technique	(Jansson,	Fowelin,	Vonschenck,	Smith,	&	Lonnroth,	1993)	and	the	formula:		
Recovery	of	inulin	in	vitro/Recovery	of	insulin	in	vitro	=	Recovery	of	inulin	in	vivo/Recovery	of	insulin	in	vivo		
2.2.8.3	Interstitial	to	plasma	(I:P)	ratio.		This	represents	the	ratio	of	insulin	concentration	between	the	circulation	and	ISF	and	was	calculated	as	the	ISF	insulin	concentration:	plasma	insulin	concentration	ratio.		
2.2.9	Statistical	analysis	Results	are	expressed	as	mean	±	SEM	unless	otherwise	indicated.		Differences	between	treatment	groups	were	evaluated	using	an	unpaired	Student’s	t-test.		Differences	from	baseline	within	the	group	were	analysed	using	a	one-way	ANOVA	with	Dunnett’s	post	
hoc	test.		
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3.	Results	
3.1		Validation	of	the	microdialysis	method	in	vitro		
Pore	size.	Experiments	comparing	pore	size	at	55	and	100kDa	cut-offs	showed	that	recovery	of	both	insulin	and	inulin	in	vitro	was	higher	with	the	55kDa	probe	(see	Supplemental	Data	Figure	3).	
Perfusion	fluid.	1%	BSA	delivered	at	1µl/min	consistently	provided	the	highest	recovery	of	insulin	in	each	set	of	conditions,	whereas	2%	BSA	at	2.5µl/min	consistently	provided	the	lowest	recovery	in	each	set	of	conditions.		The	optimal	conditions	for	recovery	were	silicon-coated	glass	microvials	with	silicon-coated	FEP	tubing	using	perfusion	fluid	containing	1%	BSA	perfused	at	1µl/min	(Figure	2).		These	optimum	conditions	were	then	further	tested	at	different	concentrations	of	insulin	and	inulin	to	increase	the	accuracy	of	recovery	calculations.		The	in	vitro	recovery	for	insulin	under	these	conditions	was	9.4	±	0.4%	for	3000pmol/L,	14.7	±	1.8%	for	1000pmol/L	and	3.2	±	0.1%	for	300pmol/L	(n=2).		The	in	vitro	recovery	for	inulin	under	these	conditions	was	16.7	±	5.2%	for	25µg/ml	inulin	(n=2).		Microdialysis	perfusion	fluid	for	all	in	vivo	experiments	was	therefore	prepared	using	1%	BSA	with	a	fixed	volume	infusion	rate	of	1µl/min.		
3.2	Refinement	of	microdialysis	methodology	in	vivo	The	pilot	inulin	infusion	experiments	showed	that	inulin	infused	from	-80min	achieved	a	stable	level	within	30	min	that	was	maintained	until	cessation	of	infusion	at	180min	(see	Supplementary	Data	Figure	2).			The	combined	method	validation	experiments	indicated	that	recovery	of	insulin	in	vivo	was	higher	with	a	100kDa	MW	cut-off	probe	than	the	55kDa	probe	(3.07	±	0.68	vs	1.35	±	0.10%;	see	Supplemental	Data	Figure	3).		
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3.3	Use	of	validated	microdialysis	methodology	during	HE	clamp				In	experiments	on	lean	and	obese	Zucker	rats,	inulin	concentration	reached	steady	state	at	-20min	of	the	HE	clamp	(Supplemental	Data	Figure	3).			
3.3.1	Effects	of	HE	clamp	in	lean	and	obese	Zucker	rats	MABP	was	higher	for	obese	rats	throughout	the	protocol,	whereas	HR	was	not	different	between	lean	and	obese	rats.	Neither	variable	changed	during	HE	clamp	(see	Supplementary	Data	Figure	4).			Blood	glucose	was	significantly	higher	in	obese,	than	lean	rats	throughout	the	protocol;	neither	group	changed	from	baseline	at	any	time	point	(see	Figure	3A).		In	obese	rats,	GIR	was	different	from	baseline	from	24min	onwards	from	the	onset	of	the	HE	clamp,	whereas	in	lean	rats,	GIR	was	increased	from	13min	onwards.		GIR	was	higher	for	lean	than	obese	rats	from	13min	onwards	(Figure	3B).		Plasma	insulin	concentrations	were	significantly	higher	than	their	respective	baseline	at	20	and	60min	of	the	HE	clamp	in	both	lean	and	obese	rats	(Figure	4B;	P	<	0.05).			Plasma	insulin	concentration	was	significantly	higher	in	obese,	than	lean	rats	throughout	the	protocol	(Figure	4B).		Thus,	insulin	sensitivity	(MI)	calculated	from	GIR	and	plasma	insulin	was	substantially	higher	in	lean	than	obese	rats:		(Supplemental	Data	Figure	5).		The	ISF	insulin	concentrations	measured	at	the	two	baseline	time	points	at	an	interval	of	40min	were	not	different	in	either	group	(data	not	shown;	P	=	0.56	for	obese	and	0.35	
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for	lean).		This	indicated	that	trauma,	inducing	inflammation	introduced	by	the	insertion	of	the	probe	had	stabilised	by	the	time	the	HE	clamp	began.		Data	from	these	two	time	points	were	therefore	pooled	to	give	one	baseline	value.		During	HE	clamp,	ISF	concentration	of	insulin	in	lean	rats	increased	from	66	±	11pmol/L	at	baseline	to	236	±	53pmol/L	(Figure	4A;	P	<	0.05)	and	stabilised	at	this	level.		By	contrast,	ISF	concentration	of	insulin	in	obese	rats	increased	from	643	±	165pmol/L	at	baseline	to	1087	±	243pmol/L	during	HE	clamp	(Figure	4	A,	P	=	0.07).	The	ISF	concentration	of	insulin	was	higher	in	obese	than	lean	rats	under	baseline	conditions	and	at	the	end	of	HE	clamp	(Figure	4	A;	P	<	0.05).		The	MI	calculated	from	GIR	and	ISF	insulin	was	substantially	higher	in	lean	than	obese	rats:	0.0266	±	0.0019	vs.	0.0032	±	0.0012μmol/kg/min	per	pmol/L	respectively.		The	I/P	ratio	of	insulin	was	higher	in	lean	rats	than	obese	rats	at	baseline	(Figure	4C;	0.46	±	0.04	vs.	0.23	±	0.07,	P	<	0.05).		However,	the	I/P	ratios	decreased	compared	to	baseline	at	20	and	60min	during	the	HE	clamp	in	lean	rats,	while	I/P	fell	modestly	by	20min	in	obese	rats	(Figure	4	C).		The	I/P	ratios	were	not	different	between	lean	and	obese	rats	at	20	and	60min	during	the	HE	clamp.			
4	Discussion	
	In	this	study	we	succeeded	in	making	three	novel	contributions	to	the	methodology	required	to	measure	skeletal	muscle	ISF	insulin	concentrations	in	healthy	control	rats	and	obese	Zucker	rats,	a	popular	rat	model	of	metabolic	syndrome	and	type	2	diabetes.	The	first	contribution	is	that	we	succeeded	in	scaling	down	the	required	volume	of	dialysate	and	concentration	range	of	ISF	to	levels	obtained	in	rat	muscle	ISF.		The	second	
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and	third	contribution	is	that	we	succeeded	in	optimising	the	microdialysis	methodology	in	vitro	and	in	rat	skeletal	muscle	in	vivo.		We,	therefore,	have	been	able	to	measure	for	the	first	time,	the	concentrations	of	insulin	in	ISF	of	rat	skeletal	muscle	under	baseline	conditions	(overnight	fasted)	and	during	an	HE	clamp	in	both	lean	and	obese	Zucker	rats.		Our	results	indicate	that	under	baseline	conditions,	insulin	concentrations	in	ISF	were	lower	in	lean	than	in	obese	Zucker	rats	and	that	the	plasma	insulin	concentration	was	substantially	higher	in	obese	rats.		The	baseline	I/P	insulin	concentration	ratio	was	much	higher	in	lean	than	obese	rats	implying	that	transcapillary	transport	of	insulin	is	impaired	in	the	overnight	fasted	state	in	obese	rats.		During	the	HE	clamp	ISF	insulin	increased	markedly	in	lean	rats,	whereas	the	increase	in	ISF	insulin	in	obese	rats	was	modest	despite	a	substantial,	though	not	significant,	increase	in	plasma	insulin	concentration.		As	a	result	the	I/P	ratio	became	more	similar	between	the	lean	and	obese	Zucker	rats.			
	
4.1	Validation	of	the	microdialysis	methodology	In	order	for	microdialysis	to	be	used	effectively	to	assay	ISF	insulin	particularly	in	small	rodents,	two	major	challenges	had	to	be	overcome.		Firstly	insulin	readily	adheres	to	the	types	of	material	used	for	sample	collection	and	assaying	and	secondly,	insulin	is	very	difficult	to	assay	in	concentrations	in	the	pmol/L	range	in	small	volumes	of	<15µl.		In	the	present	study,	we	showed	that	recovery	of	insulin	was	greater	under	all	conditions	when	the	tubing	and	collection	vials	were	siliconised	with	Sigmacote	prior	to	use	(Fig.	2).		We	tested	two	commercially	available	Ultra	sensitive	Insulin	ELISA	kits	and	established	the	Crystal	Chem	Ultrasensitive	Rat	Insulin	ELISA	kit	was	the	most	appropriate.		It	can	be	used	to	assay	insulin	in	small	samples	of	15µl	and	will	accurately	detect	insulin	at	concentrations	as	low	as	5.4pmol/L,	even	though	the	manufacturer’s	
	 21	
stated	range	is	17.4-11,136pmol/L.		As	the	measurement	of	insulin	is	so	vital	to	the	accurate	representation	of	the	data	and	because	the	kit	has	a	different	affinity	to	rat	and	human	insulin,	two	standard	calibration	curves	were	run	on	each	ELISA	plate,	one	using	the	rat	insulin	supplied	in	the	kit	and	the	other	with	human	insulin	spiked	into	rat	plasma.		Hence,	samples	(plasma	and	ISF)	before	the	initiation	of	insulin	infusion	were	read	off	the	rat	standard	curve	and	samples	(plasma	and	ISF)	collected	after	the	initiation	of	insulin	infusion	were	read	off	the	human	standard	curve.		This	is	particularly	important	when	comparisons	are	being	made	between	concentrations	of	insulin	measured	under	baseline	and	HE	clamp	conditions	as	it	ensures	that	both	rat	and	human	insulin	are	measured	as	accurately	as	possible.		We	used	the	external	reference	technique	to	assess	insulin	recovery	from	ISF	in	vivo	(Jansson	et	al,	1993)	by	using	inulin	because	it	has	a	molecular	weight	similar	to	insulin	and	passes	between	plasma	and	ISF	by	non-specific	transcapillary	diffusion	(Chaurasia	et	al,	2007).			For	the	external	reference	technique	to	be	accurate	it	is	essential	that	the	concentration	of	inulin	in	plasma	and	ISF	has	stabilised.		A	novel	aspect	of	the	present	study	is	that	that	we	established	that	when	inulin	was	given	by	infusion	starting	80min	before	the	HE	clamp,	a	stable	inulin	concentration	in	plasma	was	achieved	within	60min	and	was	maintained	throughout	the	HE	clamp.		This	simple	addition	to	the	protocol	avoids	the	additional	time	and	trauma	to	the	animal	caused	by	implanting	an	osmotic	mini	pump	to	deliver	inulin	as	employed	by	others	(Holmang	et	al.,	1997).		
	An	important	aspect	of	our	in	vitro	studies	was	to	test	the	available	microdialysis	probes	and	to	explore	the	composition	of	the	perfusion	fluid.		Clearly,	the	pore	size	must	be	significantly	larger	than	the	molecule	of	interest	in	order	to	allow	equilibration	across	
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the	membrane.		Probes	with	molecular	weight	cut-offs	of	50kDa	(Holmang,	Niklason,	Rippe,	&	Lonnroth,	2001;	Holmang,	Nilsson,	Niklasson,	Larsson,	&	Lonroth,	1999)	or	100kDa	(Gudbjornsdottir,	Sjostrand,	Strindberg,	Wahren,	&	Lonnroth,	2003;	Sjostrand	et	al.,	1999)	have	been	used	previously	for	measurement	of	insulin,	but	to	date,	they	have	not	been	compared.		The	present	experiments	showed	that	in	vitro,	recovery	of	both	insulin	and	inulin	was	higher	with	the	55kDa	than	100kDa	probe.		By	contrast,	in	
vivo,	recovery	of	both	insulin	and	inulin	were	better	with	the	100kDa	MW	cut-off	probe.		This	may	seem	surprising	because	increased	porosity	of	the	dialysis	membranes	leads	to	increased	internal	hydraulic	pressure	caused	by	perfusion	fluid	entering	the	probe	and	this	can	cause	ultrafiltration	that	works	against	the	diffusion	of	insulin	into	the	membrane.		Ultrafiltration	also	dilutes	the	microenvironment	surrounding	the	probe	leading	potentially	to	under-estimation	of	the	substance	of	interest	(Chaurasia	et	al.,	2007).		However,	we	took	steps	to	avoid	ultrafiltration	by	ensuring	the	outlet	tubing	was	below	the	level	of	the	animal:		hydrostatic	back	pressure	on	the	dialysis	membrane	causes	ultrafiltration	(Trickler	and	Miller	(2003)).		Further,	as	air	bubbles	in	the	tubing	may	cause	ultrafiltration	when	they	reach	the	probe,	we	expelled	them	from	the	tubing	before	it	was	inserted	into	the	tissue.		Due	to	the	low	flow	rate	of	microdialysis	fluid,	we	began	flushing	the	tubing		>30min	before	the	time	of	probe	insertion	into	the	rat	anterior	tibialis	muscle	.			In	previous	studies	it	was	shown	that	addition	of	an	osmotic	balancing	agent	such	as	dextran-70	or	BSA	(1-5%)	to	microdialysis	perfusion	fluid	when	using	100kDa	or	larger	cut-off	membranes	prevented	excessive	ultrafiltration,	by	creating	an	osmotic	pressure	that	offset	the	hydrostatic	pressure.			Such	colloids	also	helped	prevent	non-specific	adsorption	onto	the	materials	of	the	device	(Rosdahl	et	al.,	2000;	Trickler	&	Miller,	2003;	
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Gudbjornsdottir	et	al.,	2005;	Gudbjornsdottir	et	al.,	2003;	Holmang	et	al.,	1997;	Holmang	et	al.,	2001;	Holmang	et	al.,	1999;	Sjostrand	et	al.,	1999;	Sjostrand	et	al.,	2000;	Herkner	et	al.,	2003).		In	the	present	study,	we	found	that	addition	of	1%	BSA	consistently	provided	the	highest	recovery	of	insulin	in	each	set	of	conditions.			The	hydraulic	pressure	created	by	perfusion	increases	proportionally	as	flow	rate	is	increased	and	thus,	more	fluid	is	lost	from	the	probe	at	higher	flow	rates,	particularly	with	probes	of	high	molecular	weight	cut-off	(Trickler	&	Miller,	2003).		Reducing	the	flow	rate	therefore	reduces	error	and	increases	recovery	(Lonnroth	&	Strindberg,	1995).		Flow	rates	of	1,	2,	or	2.5μl/min	were	used	in	previous	studies	to	measure	insulin	in	ISF	(Holmang	et	al.,	1999;	Sjostrand	et	al.,	1999;	Holmang,	Muller,	Andersson,	&	Lonnroth,	1998;	Jansson	et	al.,	1993).		In	the	present	study,	we	established	that	1%	BSA	delivered	at	1µl/min	consistently	provided	the	highest	recovery	of	insulin	in	each	condition.			In	view	of	these	findings,	perfusion	fluid	containing	1%	BSA	delivered	at	1µl/min	was	used	for	all	experiments	on	lean	and	obese	Zucker	rats.		Although	7000pmol/L	was	the	insulin	concentration	we	routinely	used	to	assess	the	optimum	conditions	for	the	measurement	of	insulin,	we	knew	the	concentration	required	might	vary	depending	on	the	prevailing	insulin	concentration.		Recovery	of	insulin	was	therefore	tested	at	insulin	concentrations	of	300,	3000	and	7000pmol/L	corresponding	to	plasma	insulin	concentration	in	lean	Zuckers	under	baseline	conditions,	obese	Zuckers	at	baseline	and	lean	Zuckers	at	HE	clamp	conditions	and	obese	Zuckers	during	HE	clamp	respectively.		This	further	increases	the	accuracy	of	the	method.		As	inulin	concentrations	in	plasma	were	similar	and	constant	in	lean	and	obese	rats,	only	one	concentration	of	inulin	was	used	for	assessment	of	in	vitro	recovery.	
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4.2	Effects	of	HE	clamp	in	lean	and	obese	Zucker	rats		As	expected,	under	baseline	conditions,	the	obese	rats	were	hyperglycaemic	compared	to	the	lean	rats.		Both	groups	were	fixed	at	euglycemia	throughout	the	HE	clamp	as	intended.		This	was	achieved	by	increasing	GIR	to	higher	levels	in	lean,	than	obese	rats	and	the	increase	from	baseline	was	required	earlier	in	the	lean	rats.		As	expected,	plasma	insulin	concentrations	were	significantly	lower	in	the	lean	than	obese	rats.		In	fact,	only	during	the	steady	state	of	the	HE	clamp	did	plasma	insulin	concentrations	in	lean	rats	reach	the	baseline	concentration	seen	in	the	obese	rats.		Thus,	insulin	sensitivity	(MI)	calculated	from	plasma	insulin	was	~8fold	higher	for	lean,	than	obese	rats.			The	insulin	concentrations	we	measured	in	ISF	were	lower	than	plasma	concentrations	in	lean	rats	under	baseline	conditions,	indicating	that	the	capillary	bed	acts	as	a	functional	barrier	to	the	movement	of	insulin.		This	is	consistent	with	established	evidence	that	an	arterial-interstitial	gradient	exists	for	insulin	(Sjostrand	et	al.,	1999).		Indeed,	the	only	other	study	to	measure	baseline	ISF	insulin	concentrations,	–	in	healthy	lean	men	rather	than	rats	(Herkner	et	al.,	2003)	–	also	reported	an	insulin	gradient:	48	±	8	pmol/L	in	plasma	versus	19	±	4	pmol/L	in	ISF	under	basal	conditions.		Our	finding	that	baseline	concentrations	of	insulin	in	ISF	in	obese	rats	were	significantly	higher	than	in	lean	rats,	but	lower	than	in	plasma,	is	novel	and	indicates	that	in	obese	rats	also,	the	capillary	bed	acts	as	a	functional	barrier	for	transcapillary	insulin	transport.		However,	as	the	I/P	ratio	was	significantly	lower	in	obese	than	in	lean	rats	under	baseline	conditions	(0.23	±	0.07	vs.	0.46	±	0.03)	thus,	it	seems	that	the	capillary	transfer	of	insulin	is	blunted	in	obese	rats	even	under	baseline	conditions.		
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	The	I/P	ratio	decreased	from	0.65	±	0.25	to	0.17	±	0.07	in	lean	and	from	0.23	±	0.07	to	0.11	±	0.02	in	obese	rats	during	the	HE	clamp	(by	~74%	and	~52%,	respectively)	such	that	the	I/P	ratio	in	lean	rats	during	HE	clamp	was	similar	to	that	of	obese	rats	under	basal	conditions.		Similarly,	Herkner	et	al.,	(2003)	reported	that	in	young	men	the	I/P	ratio	decreased	substantially	from	~0.48	under	basal	conditions	to	~0.12	during	an	HE	clamp.		Interestingly,	they	found	no	change	in	the	I/P	ratio	when	plasma	insulin	reached	the	same	peak	value	during	the	glucose	tolerance	test	and	concluded	this	reflects	a	transcapillary	insulin	transport	mechanism	that	is	partly	saturable	even	during	short-term	steady-state	hyperinsulinaemia.		The	new	results	of	the	current	study	suggest	that	transcapillary	insulin	transport	might	be	closer	to	saturation	in	obese	than	in	lean	Zucker	rats	for	they	achieved	a	similar	I/P	ratio	to	that	of	lean	rats	at	a	much	higher	plasma	concentration	of	insulin.			In	contrast	to	the	present	results,	Holmang	et	al.,	(1997)		reported	that	during	HE	clamp	at	two	different	levels	of	hyperinsulinaemia,	a	plasma/ISF	insulin	gradient	existed	in	lean	Zucker	rats,	but	not	in	obese	Zucker	rats.		They	therefore	concluded	that	transcapillary	transport	of	insulin	is	not	rate	limiting	for	glucose	metabolism	in	muscle	of	obese	Zucker	rats.		Their	results	are	difficult	to	compare	with	the	present	findings	not	only	because	they	made	no	measurements	of	ISF	insulin	under	baseline	conditions,	but	also	because	they	used	smaller	(50kDa)	molecular	weight	cut-off	microdialysis	probes,	a	less	sensitive	insulin	assay	and	did	not	make	allowances	for	cross-reactivity	between	human	and	rat	insulin.		We	suggest	that	the	insulin	concentrations	we	have	estimated	in	the	present	study	are	more	likely	to	be	accurate	than	those	of	Holmang	et	al.,	(1997).		
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The	relatively	modest	increase	in	ISF	insulin	we	measured	in	the	obese	rats	during	HE	clamp	could	be	explained	by	an	impaired	insulin-induced	dilatation	of	resistance	and	terminal	arterioles	and	consequent	blunted	increase	in	muscle	blood	flow	and	recruitment	of	additional	capillary	surface	area	for	transcapillary	insulin	transport,	and/or	by	an	impaired	increase	in	TET	of	insulin	(see	Barrett	et	al,	2011;	Wagenmakers	et	al,	2016).			Insulin	causes	dilatation	by	activating	eNOS	via	increased	ser1177	phosphorylation	(see	Munyiappa	et	al,	2006),	while	NO-induced	nitrosylation	of	proteins	is	critically	important	for	insulin-induced	increase	in	TET	(Wang	et	al,	2013).	In	related	studies	involving	HE	clamps	comparable	to	those	of	the	present	study,	we	found	that	hindlimb	muscle	blood	flow	increased	substantially	in	lean	Zucker	rats,	but	not	in	obese	Zucker	rats	(Stride	et	al,	2012).		Further,	HE	clamp	activated	increased	ser1177	phosphorylation	of	eNOS	in	terminal	arterioles,	but	not	capillaries	of	lean	Zucker	rats,	whilst	decreasing	eNOS		ser1177	phosphorylation	in	terminal	arterioles	and	capillaries	of	obese	Zucker	rats	(Cocks	et	al,	2013).			Thus,	it	seems	highly	likely	that	the	impaired	transcapillary	transport	of	insulin	in	obese	Zucker	rats	during	HE	clamp	is	at	least	partly	dependent	on	reduced	ability	of		arteriolar	insulin	receptors	to	induce	dilatation	(Wagenmakers	et	al,	2016).		Our	results	give	no	direct	insight	into	differences	in	the	insulin	sensitivity	of	TET	between	lean	and	obese	rats.			However,	if	muscle	insulin	sensitivity	estimated	from	GIR	and	ISF	insulin	concentrations	rather	than	plasma	ISF		(see	Figures	3	and	4),		it	seems	the	sensitivity	is	15-fold	greater	in	lean,	than	obese	rats.		This	suggests	that	a	large	part	of	the	insulin	resistance	shown	by	obese	Zucker	rats	is	located	at	the	level	of	the	skeletal	muscle	fibres.				
	
Summary	
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The	present	study	allowed	us	to	refine	and	validate	the	in	vivo	microdialysis	methodology	for	determination	of	insulin	concentration	in	the	ISF	of	skeletal	muscle	in	rats.		Notably,	we	established	it	is	possible	to	quantify	differences	in	ISF	insulin	concentration	between	lean	and	obese	Zucker	rats	under	basal	concentrations.		Future	studies	will	need	to	explore	the	broader	validation	of	this	approach	in	experimental	animal	models.		For	instance,	staggered	microdialysis	sampling	combined	with	muscle	blood	flow	recordings	may	allow	further	elucidation	of	the	vascular	and	TET	components	of	transcapillary	insulin	transport.		It	would	also	be	interesting	to	compare	the	effects	of	similar	ISF	concentrations	of	insulin	in	lean	and	obese	rats	on	glucose	uptake	in	the	two	strains.	This	would	be	expected	to	give	a	more	accurate	measure	of	insulin	sensitivity.		
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Figure	1.	Protocol	used	for	the	measurement	of	insulin	with	microdialysis	during	
hyperinsulinaemic-euglycaemic	clamp.	Probe	insertion	was	at	-120	minutes.	ISF	samples	were	collected	every	40	minutes	from	-120	minutes.	Inulin	infusion	began	at	-80	minutes	and	continued	throughout	the	protocol.	HE	clamp	protocol	started	at	0	minutes	and	continued	for	80	minutes.	Insulin	infusion	was	constant	throughout	the	protocol.	Glucose	infusion	was	varied	in	order	to	maintain	blood	glucose	concentration.	Downward	arrows	represent	plasma	samples.		
Figure	2.	FED	analysis	of	in	vitro	recovery	of	insulin.	FED	analysis	was	completed	to	compare	material	of	collection	vial	(glass	or	plastic),	concentration	of	bovine	serum	albumin	(1	or	2%	BSA),	rate	of	perfusion	fluid	(1,	2	or	2.5µl/min)	and	Sigmacote®	treatment	of	equipment	or	not	(Sigmacote®/No	Sigmacote®).	Bars	represent	the	mean	of	two	measurements	taken	under	those	conditions.		
Figure	3.	Blood	glucose	concentration	(BG)	and	glucose	infusion	rate	(GIR)	for	
lean	and	obese	Zucker	rats	during	hyperinsulinaemic	euglycaemic	clamp	with	
microdialysis.	Graphs	show	BG	(A)	and	GIR	(B).	Symbols	represent	obese	and	lean	groups	(spherical	black	and	square	white,	respectively).	Values	are	mean	±	SEM.	†	P	<	0.05	obese	versus	lean	control	group.	*	P	<	0.05	versus	baseline.		
Figure	4.	Plasma	and	interstitial	insulin	concentrations	and	the	ratio	between	the	
two	(I/P	ratio)	for	lean	and	obese	Zucker	rats	during	hyperinsulinaemic	
euglycaemic	clamp	with	microdialysis.	Graphs	show	plasma	(A)	and	interstitial	(B)	insulin	concentrations	and	the	I/P	ratio	(C).	Symbols	represent	obese	and	lean	groups	(spherical	black	and	square	white,	respectively).	Values	are	mean	±	SEM.	†	P	<	0.05	obese	versus	lean	control	group.	*	P	<	0.05	versus	baseline.			 	
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